膀胱癌液体活检miRNA风险评分:从患者来源异种移植到预后分层的转化见解
该研究通过对15例膀胱癌患者来源异种移植(PDX)小鼠模型的肿瘤和匹配血浆进行miRNA测序,筛选出6个在肿瘤和血浆中同时上调且与晚期/高级别及早期进展相关的miRNA。在216例患者筛查队列中,基于RT-qPCR定量循环miRNA并构建液体活检miRNA风险评分(miRisk-score),发现高评分与NMIBC短期复发和进展相关,并改善TaT1风险分层;在MIBC中高评分与更差临床结局相关并增强临床标志物预后性能。结论认为液体活检miRNA特征可作为微创工具补充活检评估并细化膀胱癌风险分层和预后。
要点
- PDX模型筛选出6个肿瘤与血浆同步上调的miRNA,与晚期/高级别及早期进展相关。
- NMIBC中miR-375和miR-4488升高与更差预后相关,高miRisk-score与短期复发和进展相关。
- MIBC中miR-1290和miR-193b与更差生存相关,高miRisk-score与更差临床结局相关并提升临床标志物预后性能。
核心结论
- 液体活检miRNA特征可作为微创工具补充活检评估,并细化膀胱癌风险分层和预后。
研究设计与样本
- 对15例膀胱癌PDX小鼠模型的肿瘤和匹配血浆进行miRNA测序。
- 筛查队列共216例患者,采用RT-qPCR(3'端poly(A)加尾法)定量循环miRNA。
- 使用Cox回归模型构建针对NMIBC和MIBC的液体活检miRNA风险评分(miRisk-score)。
主要发现
- miRNA测序鉴定出6个miRNA(miR-100、miR-1246、miR-1290、miR-193b、miR-375、miR-4488)在肿瘤和血浆中同时上调,并与PDX模型的晚期/高级别及早期进展相关。
- 在筛查队列中,miR-375和miR-4488升高与NMIBC更差预后相关,miR-1290和miR-193b与MIBC更差生存相关。
- 较高的miRisk-score与NMIBC短期复发和进展相关,且miRisk-score拟合的多变量模型改善了TaT1风险分层。
- 较高的miRisk-score与MIBC更差临床结局相关,并增强了临床标志物的预后性能。
临床怎么用
- 液体活检miRNA风险评分可作为微创工具,辅助膀胱癌风险分层和预后评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bladder cancer (BlCa) surveillance requires lifelong invasive monitoring, imposing substantial patient burden and healthcare costs. This underscores the need for minimally-invasive precision medicine approaches. Herein, we investigated the circulating miRNome of BlCa patients to assess its clinical and translational utility. METHODS: miRNA-seq was performed on tumors and matched plasma samples from 15 patient-derived xenograft (PDX) mouse models. The screening cohort of the study consisted of 216 patients, and circulating miRNAs were quantified by RT-qPCR following 3'-end poly(A)-tailing. Cox regression models were used to develop liquid biopsy-based miRNA risk-scores (miRisk-scores), for non-muscle invasive (NMIBC) and muscle invasive BlCa (MIBC). RESULTS: miRNA-seq identified six miRNAs (miR-100, miR-1246, miR-1290, miR-193b, miR-375, miR-4488) that were concurrently upregulated in tumors and plasma, and correlated with advanced stage/grade and early progression in PDX mouse models. In our screening cohort, elevated miR-375 and miR-4488 were associated with poorer NMIBC prognosis, whereas miR-1290 and miR-193b with worse survival in MIBC. Higher miRisk-scores were associated with short-term relapse and progression in NMIBC, while miRisk score-fitted multivariate models improved TaT1 risk-stratification. Moreover, higher miRisk-scores correlated with worse clinical outcomes in MIBC, and enhanced the prognostic performance of clinical markers. CONCLUSION: Overall, liquid biopsy miRNA signatures offer a minimally-invasive tool to complement biopsy-based assessments and refine BlCa risk-stratification and prognosis.
引用
- Papadimitriou MA, Pilala KM, Panoutsopoulou K, et al. Liquid biopsy miRNA risk score in bladder cancer: Translational insights from patient-derived xenografts to prognostic stratification. Eur J Cancer. 2026. PMID: 42594670. doi:10.1016/j.ejca.2026.116987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。